{
  "company": "中普康睿河北生物科技有限公司",
  "location": "石家庄高新区兴安大街116号润江总部国际7号楼",
  "grade": "B",
  "focus": "个体化用药基因检测（药物基因组学PGx）",
  "founded": "2017-12-18",
  "salesperson": "刘虹晶",
  "region": "华北",
  "qualifications": ["高新技术企业"],
  "nmpa_certificates": [
    {
      "regNo": "国械注准20243400171",
      "product": "MTHFR基因多态性检测试剂盒（PCR-荧光探针法）",
      "approved": "2024-01-26",
      "category": "三类IVD",
      "notes": "叶酸代谢/甲氨蝶呤毒性预测——个体化用药基础检测"
    }
  ],
  "core_patents": [
    {
      "id": "CN112080563B",
      "title": "一种检测慢性病精准用药基因的试剂盒",
      "filed": "2020-09-01",
      "granted": "2021-04-30",
      "scope": "42种药物相关的106种基因中197个突变位点",
      "significance": "覆盖高血压、糖尿病、心血管等慢性病用药基因检测，是中普康睿核心技术护城河"
    }
  ],
  "productLines": [
    {
      "category": "细菌耐药基因检测",
      "status": "已上市（推断）",
      "tech": "PCR-荧光探针法",
      "notes": "启信宝企业简介提及"
    },
    {
      "category": "慢性病个体化用药基因检测",
      "status": "核心产品线",
      "tech": "PCR-荧光探针法",
      "notes": "基于CN112080563B专利，覆盖42药/106基因/197位点。核心市场:高血压(ACE/AGTR1/CYP2D6等)、糖尿病、心血管(他汀类SLCO1B1/ApoE等)、抗凝(华法林VKORC1/CYP2C9)"
    },
    {
      "category": "MTHFR基因多态性检测",
      "status": "已获证(2024-01)",
      "tech": "PCR-荧光探针法",
      "regNo": "国械注准20243400171",
      "notes": "叶酸代谢能力评估，妇产科/心内科基础检测项目。市场竞争激烈（友芝友/华大/达安等均有同类产品）"
    },
    {
      "category": "肿瘤个体化用药基因检测",
      "status": "研发/报证中",
      "tech": "PCR-荧光探针法（推断含多重PCR）",
      "notes": "启信宝简介提及。可能覆盖EGFR/KRAS/BRAF等肿瘤靶向药相关基因。需关注2026年2月可能的新注册证（国械注准20263400423）"
    }
  ],
  "collaborations": [
    "北京中科院（联合研发）",
    "上海复旦大学（联合研发）"
  ],
  "marketPosition": {
    "segment": "药物基因组学(PGx)检测试剂",
    "competitors": ["武汉友芝友", "北京华大基因", "圣湘生物", "北京宏微特斯", "江苏康为世纪"],
    "differentiation": "慢性病精准用药全覆盖(42药)的试剂盒方案，在广度上有优势",
    "targetCustomers": "医院检验科/病理科、第三方医学检验所、体检中心"
  },
  "rawMaterialDemand": {
    "currentProducts": ["MD2031 qPCR预混液", "MD2031-1 qPCR预混液"],
    "estimatedAnnualDemand": "5000-50000T（基于ERP采购频率和单次批量）",
    "potentialNewDemand": [
      "多重qPCR预混液（肿瘤Panel需要多基因同时检测）",
      "可冻干qPCR预混液（试剂盒常温储运需求）",
      "直扩预混液（简化操作流程，适配基层医院）",
      "UNG防污染系统（临床PCR必须）"
    ]
  },
  "baoruiOpportunity": {
    "currentShare": "100%（当前唯一供应商）",
    "growthDrivers": [
      "MTHFR获证后进入放量期→MD2031采购量增长",
      "慢性病Panel若获证→多基因检测需要更多PCR试剂",
      "肿瘤产品线若推进→多重qPCR+冻干需求",
      "合作中科院/复旦→研发活跃，新品管线多"
    ],
    "risks": [
      "MTHFR市场竞争激烈，若销量不达预期可能压缩采购",
      "慢性病/肿瘤Panel注册周期长(2-3年)，短期爆发力有限",
      "需确认是否存在其他原料供应商（当前CRM无记录，但需警惕）"
    ],
    "recommendedActions": [
      "优先推荐MD2031可冻干版本→配合其试剂盒常温储运需求",
      "推荐含UNG防污染的qPCR预混液→满足临床PCR必须的防污染要求",
      "关注其2026年新注册证动态→第一时间匹配原料方案",
      "提供注册支持文档（原料合规文件/稳定性数据）→帮助其产品注册"
    ]
  },
  "products": [
    {
      "code": "MD2031",
      "name": "qPCR预混液",
      "erpSales": 109530,
      "notes": "主采产品，自2024年起稳定复购"
    },
    {
      "code": "MD2031-1",
      "name": "qPCR预混液（特定版本）",
      "erpSales": 10800,
      "notes": "2026年3月首次采购，可能用于新产品线开发"
    }
  ],
  "erpSummary": {
    "totalSales": 125370,
    "orderCount": 17,
    "firstOrder": "2024",
    "lastOrder": "2026-03",
    "may2026Orders": 2,
    "may2026Amount": 27000
  },
  "contacts": [],
  "competitors": [],
  "visitHistory": [],
  "notes": "【2026-06-29市场调研更新】1)核心赛道为药物基因组学(PGx)——慢性病+肿瘤个体化用药基因检测；2)已获MTHFR三类注册证(2024)，慢性病Panel专利(2021年授权/42药106基因197位点)；3)2026年2月可能有新注册证获批；4)合作中科院+复旦，研发实力有保障；5)当前宝锐100%供应MD2031，无竞品介入迹象；6)成长路径清晰：MTHFR→慢性病Panel→肿瘤Panel，原料需求将随产品线扩张而增长。CRM中无竞品测试记录。",
  "created": "2026-06-29",
  "updated": "2026-06-29"
}